Antibiotics do not lower Avastin infection risk

Article

The incidence of endophthalmitis is independent of whether prophylactic antibiotics are administered in conjunction with Avastin (bevacizumab) injections, according to results of a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Prophylactic antibiotics do not lower the incidence of endophthalmitis in patients receiving Avastin (bevacizumab) injections, according to results of a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Carsten H. Meyer, MD of the Augenklinik at Bonn University, Germany and colleagues conducted a retrospective study of two groups of patients receiving 1.25 mg/0.05 ml Avastin after an incubation of 5% povidone-iodine for 60 seconds in the conjunctival fornix. The first set of subjects (Group A; n=984) underwent the injection as an outpatient procedure and received no prophylactic antibiotics after the injection. In the second set (Group B; n=860), patients were admitted to hospital for one day and received three days of topical antibiotics following the injection.

The subjects of Group A had a zero incidence of post-injection endophthalmitis; two patients developed intraocular uveitis, which was treated successfully with topical steroids. In Group B, the two cases of post-injection endophthalmitis that developed after five days were treated with vitrectomy.

The researchers concluded that administration of prophylactic antibiotics was unable to eliminate endophthalmitis in these cases; when considering this factor, it is irrelevant whether the injection of Avastin is administered on an inpatient or outpatient basis.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.